BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

– BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and equally share profits – Helsinn Group will have an exclusive license to co-develop, manufacture and commercialize infigratinib in such indications outside of the U.S., excluding China, Hong Kong and Macau […]

BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting

– Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept – At Doses up to 180 mg Twice Daily, Encaleret was Well-Tolerated with No Serious Adverse Events and No Adverse Events of Moderate or Severe Intensity Reported After […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, March 2, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 1, 2021, the compensation committee of BridgeBio’s board of directors granted 17 new employees restricted stock units for an aggregate of 30,510 shares of the Company’s common stock. All of […]